BioPharma Dive 27. Feb. 2026 Atrium spins out of Avidity, aiming to target rare heart diseases with RNA
BioPharma Dive 6. Feb. 2026 White House’s online service for drug sales debuts with limited impact on prices
BioPharma Dive 14. Jan. 2026 JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view